IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

被引：34
作者：
Ritter, Christian [1 ,3 ]
Foerster, Dominik [2 ]
Albrecht, Philipp [2 ]
Hartung, Hans-Peter [2 ]
Kieseier, Bernd C. [2 ]
Lehmann, Helmar C. [1 ]
机构：
[1] Univ Cologne, Dept Neurol, D-50937 Cologne, Germany
[2] Univ Dusseldorf, Fac Med, Dept Neurol, D-40225 Dusseldorf, Germany
[3] Forschungszentrum Julich, Inst Neurosci & Med INM3, D-52428 Julich, Germany
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2014年 / 274卷 / 1-2期
关键词：
B-cell activating factor; CIDP; Immune neuropathy; Cytokine; Therapy; Treatment; B-LYMPHOCYTE STIMULATOR; ACTIVATING FACTOR BAFF; BLOOD-PLASMA CONCENTRATIONS; NECROSIS-FACTOR FAMILY; INTRAVENOUS IMMUNOGLOBULIN; T-CELL; THERAPEUTIC TARGETS; BAFF/APRIL SYSTEM; POLYRADICULONEUROPATHY; OVEREXPRESSION;
D O I：
10.1016/j.jneuroim.2014.06.007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Recent studies indicate that the cytokine B-cell activating factor (BAFF) is involved in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is standard treatment for CIDP and is known to rapidly modulate increased serum levels of pro-inflammatory cytokines. We evaluated the expression profile of BAFF and its corresponding BAFF-receptor in samples from CIDP patients, focusing on rapid changes before and after IVIg treatment In CIDP patients BAFF serum concentrations were elevated compared to controls. Treatment with high-dose IVIg restored those elevated BAFF serum levels. Whereas treatment with IVIg did not affect BAFF production in monocytes, antibodies against BAFF could be detected in IVIg preparations, which may explain the short-term decrease of BAFF levels after IVIg treatment. Our data suggest that BAFF plays an important role in the pathogenesis of CIDP and may serve as marker for IVIg treatment response. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码：225 / 229
页数：5
相关论文
共 47 条
[1]   The expression of BAFF in the muscles of patients with dermatomyositis [J].
Baek, Ahmi ;
Park, Hyung Jun ;
Na, Sang-Jun ;
Shim, Dong Suk ;
Moon, Joon-Shik ;
Yang, Young ;
Choi, Young-Chul .
JOURNAL OF NEUROIMMUNOLOGY, 2012, 249 (1-2) :96-100
[2]   Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - A new mechanism of action? [J].
Bick, Sandra ;
Tschernatsch, Marlene ;
Karg, Anne ;
Fuehlhuber, Verena ;
Trenczek, Tina E. ;
Faltermeier, Kathrin ;
Hackstein, Holger ;
Kaps, Manfred ;
Blaes, Franz .
JOURNAL OF NEUROIMMUNOLOGY, 2013, 256 (1-2) :84-90
[3]   Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders [J].
Buttmann, Mathias ;
Kaveri, Srini ;
Hartung, Hans-Peter .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (08) :445-457
[4]  
Cheema GS, 2001, ARTHRITIS RHEUM-US, V44, P1313, DOI 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO
[5]  
2-S
[6]   Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcγRII expression in patients with chronic inflammatory neuropathies [J].
Créange, A ;
Gregson, NA ;
Hughes, RAC .
JOURNAL OF NEUROIMMUNOLOGY, 2003, 135 (1-2) :91-95
[7]   B cells as therapeutic targets in autoimmune neurological disorders [J].
Dalakas, Marinos C. .
NATURE CLINICAL PRACTICE NEUROLOGY, 2008, 4 (10) :557-567
[8]   Advances in the diagnosis, pathogenesis and treatment of CIDP [J].
Dalakas, Marinos C. .
NATURE REVIEWS NEUROLOGY, 2011, 7 (09) :507-517
[9]   Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy [J].
Eftimov, Filip ;
Winer, John B. ;
Vermeulen, Marinus ;
de Haan, Rob ;
van Schaik, Ivo N. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12)
[10]   Elevated B-cell activating factor BAFF, but not APRIL, correlates with CSF cerebellar autoantibodies in pediatric opsoclonus-myoclonus syndrome [J].
Fuehlhuber, V. ;
Bick, S. ;
Kirsten, A. ;
Hahn, A. ;
Gerriets, I. ;
Tschernatsch, M. ;
Kaps, M. ;
Preissner, K. T. ;
Blaes, F. ;
Altenkaemper, S. .
JOURNAL OF NEUROIMMUNOLOGY, 2009, 210 (1-2) :87-91
12345